Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.

Also called NCT05836740

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,724 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05836740
Other papers using this trial's data
  • Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial Lancet (London, England), 2026-02-14 DOI, PubMed 41628627

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05836740. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-19 (actual); primary completion 2024-05-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
Acronym
EMPHASIS
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Minocycline hydrochloride capsule
Intervention (Drug)
Placebo capsules of Minocycline hydrochloride capsules
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05836740
Content hash
4bcb17a2b81dfb01cfce34abbe480e954046bc0dfe94f70d2c95ded5d6851350